Partnership to drive continued improvement in patient care
and diabetes management
BOSTON, May 14, 2024
/PRNewswire/ -- Glytec, whose industry leading SaaS platform
empowers collaborative diabetes management and insulin dosing from
the hospital to the home, is pleased to announce a partnership with
University Hospitals (UH), a leading academic medical center and
community hospital network based in Cleveland, Ohio. This collaboration marks a
significant milestone in the advancement of diabetes care and
underscores both organizations' momentum and commitment to
improving patient outcomes, quality of care, cost of care, and the
patient experience.
Dr. Peter Pronovost, Chief
Clinical Transformation Officer at UH and global leader in patient
safety and quality improvement, played a pivotal role in
facilitating this partnership along with Dr. Betul Hatipoglu, Vice Chair for UH System
Clinical Affairs & Medical Director for UH Diabetes and
Metabolic Center. Together, their transformational leadership and
dedication to enhancing healthcare delivery have been instrumental
in driving initiatives aimed at optimizing patient care processes
and experiences, including the integration of innovative
technologies like Glytec's FDA-cleared Glucommander® solution.
"We are very excited for this partnership and eager to implement
the Glytec solution to positively impact patient outcomes,
experience, and quality of care in our journey toward Zero Harm,"
declared Dr. Pronovost, who leads strategic initiatives to improve
value across the UH health system.
Through this strategic alliance, Glytec will deliver its insulin
management software platform first to UH Cleveland Medical Center,
empowering healthcare professionals with the tools needed to
advance insulin management and improve patient care. Glytec's
software platform, built on over 100 patents and over 100
whitepapers and medical publications, leverages evidence-based
algorithms and real-time data analysis to personalize dosing for
all insulin-requiring patients. One-third of all hospitalized
patients nationally require insulin therapy to regulate high blood
sugar during their stay,[1] which reduces the risks of
severe hypoglycemia, severe hyperglycemia, and other
diabetes-related complications in alignment with CMS' Hospital Harm
eClinical Quality Measures (eCQMs) and new proposed rule to mandate
reporting of measures related to Severe Hypoglycemia and Severe
Hyperglycemia for the CY 2026 reporting period.[2]
Glytec's Chief Medical Officer, Dr. Jordan Messler, echoed the significance of Dr.
Pronovost's contributions, emphasizing, "Dr. Pronovost's leadership
and commitment to improving patient safety sparked my interest in
quality improvement. His work nationally and at his institution
aligns perfectly with Glytec's mission to make insulin therapy
safer and more effective. We are honored to collaborate with him
and University Hospitals to drive positive change in diabetes
management."
This partnership highlights Glytec's commitment to collaborating
with healthcare leaders and institutions to advance the standard of
care for patients and continue to innovate in the diabetes
technology sector. By harnessing the expertise of Drs. Pronovost
and Hatipoglu, as well as the clinical excellence of University
Hospitals, Glytec aims to further revolutionize diabetes management
and improve patient outcomes on a national scale.
About University Hospitals
University Hospitals (UH) is a nationally recognized academic
medical center and network of hospitals, outpatient centers, and
primary care physicians serving patients throughout Northeast Ohio. UH provides comprehensive
medical care and contributes to medical research and education.
UH's mission is to heal, to teach, and to discover, and its vision
is Advancing the Science of Health and the Art of Compassion. With
a commitment to patient-centered care and innovation, UH delivers
world-class healthcare to the communities it serves.
About Glytec
Glytec's industry leading SaaS platform,
trusted by 350+ hospitals, empowers collaborative diabetes
management and insulin dosing, improving patient
outcomes, reducing length of stay, and streamlining workflows
while delivering a 6-8x ROI. The first-ever FDA-cleared cloud-based
insulin management software is EMR-integrated, easy to set up, and
validated by over 100 patents and over 100 publications. The Glytec
Glucommander® solution, with clinical decision support, workflow
alerts, patient monitoring, at-risk patient identification, and
AI-driven analytics, is supported by a mission-driven team
dedicated to helping healthcare leaders, clinicians and
patients promote health equity and improve diabetes
outcomes from hospital to home. We are on a mission, join
us.
For more information, follow Glytec on X (@Glytec) and
LinkedIn, or visit www.glytec.com.
Sources
[1] Umpierrez, et al. J of Clin Endo &
Met. 87, no. 3 (March 2002):
978-82. https://doi.org/10.1210/jcem.87.3.8341.
[2]
https://www.cms.gov/newsroom/fact-sheets/fy-2025-hospital-inpatient-prospective-payment-system-ipps-and-long-term-care-hospital-prospective
View original content to download
multimedia:https://www.prnewswire.com/news-releases/glytec-and-university-hospitals-uh-forge-strategic-partnership-302143931.html
SOURCE Glytec